mFOLFOXIRI + panitumumab versus FOLFOXIRI as first-line treatment in patients with RAS wild- type metastatic colorectal cancer m(CRC): A randomized phase II VOLFI trial of the AIO (AIO- KRK0109).
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.3509
Abstract: 3509Background: Triple chemotherapy with an anti-EGFR reported promising activity with some safety concerns in single arm phase II trials. This trial evaluated activity and safety of mFOLFOXIRI + p... read more here.
Keywords: phase; trial; versus folfoxiri; mfolfoxiri panitumumab ... See more keywords
Panitumumab versus cetuximab in patients with wild-type KRAS exon 2 metastatic colorectal cancer who received prior bevacizumab therapy: A combined analysis of individual patient data from ASPECCT and WJOG6510G.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.4_suppl.745
Abstract: 745Background: The ASPECCT (Price T, et al. Eur J Cancer 2016) and WJOG6510G (Sugimoto N, et al. ASCO-GI 2017) trials demonstrated noninferiority of panitumumab (Pmab), compared with cetuximab (Cma... read more here.
Keywords: versus cetuximab; panitumumab versus; cetuximab patients; cancer ... See more keywords